← Leaderboards
Suresh B Boppana
University Of Alabama At Birmingham
$9,522,148
Attributed
$9,886,025
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,855,757 · 14
By mechanism
R01$4,278,966 · 2
U01$4,240,259 · 2
N01$3,788,975 · 2
P01$499,104 · 1
K18$350,653 · 1
R21$327,664 · 1
Top collaborators
- William J Britt5 shared
- Swetha Geetha Pinninti5 shared
- Deenan Pillay3 shared
- Karen B Fowler1 shared
- Shannon A Ross1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- William J Britt$28,989,956
- Swetha Geetha Pinninti$90,176
- Gail Wiliams Wertz$7,689,443
- Michael S Reddy$2,612,789
- Kent G Palcanis$294,208
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusCongenital InfectionSensorineural Hearing LossInfectionPreventChildClinical ResearchResearch PersonnelVariantLifeImmune ResponseHuman SubjectVaccine DevelopmentInfantSecondary ToViralImmuneSpecimenVirus ReplicationVaccinesReportingResponseImmunityAntiviral Agents
Grant awards (38)
Adaptive Immunity and Persistent SARS-CoV-2 Replication$1,512,103
U01 · FY2023 · CA · contact PI
Adaptive Immunity and Persistent SARS-CoV-2 Replication$675,412
U01 · FY2022 · CA · contact PI
Adaptive Immunity and Persistent SARS-CoV-2 Replication$599,569
U01 · FY2022 · CA · contact PI
Project-002$270,527
U01 · FY2022 · CA · contact PI
Adaptive Immunity and Persistent SARS-CoV-2 Replication$1,182,648
U01 · FY2020 · CA · contact PI
International Congenital CMV Conference and CMV Workshop$29,540
R13 · FY2019 · DC · contact PI
Acquisition of HCMV from breast milk-correlates of protection$710,978
R01 · FY2017 · AI · contact PI
Acquisition of HCMV from breast milk-correlates of protection$712,448
R01 · FY2016 · AI · contact PI
Genetic causes as co-factors in cytomegalovirus associated hearing loss$175,514
K18 · FY2016 · DC · contact PI
Congenital CMV infection in the era of Option B in South Africa$141,090
R21 · FY2016 · HD
Congenital CMV infection in the era of Option B in South Africa$17,106
R21 · FY2016 · HD
Acquisition of HCMV from breast milk-correlates of protection$703,280
R01 · FY2015 · AI · contact PI
Genetic causes as co-factors in cytomegalovirus associated hearing loss$175,139
K18 · FY2015 · DC · contact PI
Congenital CMV infection in the era of Option B in South Africa$169,468
R21 · FY2015 · HD
Acquisition of HCMV from breast milk-correlates of protection$662,854
R01 · FY2014 · AI · contact PI
R&D CMV RELATED HEARING LOSS AND FEASIBILITY OF CMV SCREENING$591,525
N01 · FY2012 · DC · contact PI
R&D CMV RELATED HEARING LOSS AND FEASIBILITY OF CMV SCREENING$1,300,000
N01 · FY2011 · DC · contact PI
Congenital CMV Infection and Hearing Loss in Rural Indian Population$69,029
R03 · FY2010 · HD · contact PI
R&D CMV RELATED HEARING LOSS AND FEASIBILITY OF CMV SCREENING$1,897,450
N01 · FY2009 · DC · contact PI
Congenital CMV Infection and Hearing Loss in Rural Indian Population$72,500
R03 · FY2009 · HD · contact PI
CONGENITAL CMV INFECTION$1,107
M01 · FY2007 · RR · contact PI
CONGENITAL CMV INFECTION$25,615
M01 · FY2006 · RR · contact PI
MECHANISMS AND ANTIVIRAL THERAPY OF HEARING LOSS IN CONGENITAL CMV INFECTION$4,230
M01 · FY2006 · RR · contact PI
The Natural History of CMV-Related Hearing Loss and the Feasibility of-260000008$0
N01 · FY2006 · DC · contact PI
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$145,000
R01 · FY2005 · DC
CONGENITAL CMV INFECTION$58,959
M01 · FY2005 · RR
PROJECT 3: MECHANISMS AND ANTIVIRAL THERAPY OF HEARING LOSS IN CONGENITAL CMV$14,240
M01 · FY2005 · RR
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$103,999
R01 · FY2004 · DC
Congenital CMV infection$73,055
M01 · FY2004 · RR
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$72,500
R01 · FY2004 · DC
Mechanisms and Antiviral Therapy of Hearing Loss in CMV$21,861
M01 · FY2004 · RR
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$303,181
R01 · FY2003 · DC
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$294,727
R01 · FY2002 · DC
MECHANISMS AND ANTIVIRAL THERAPY OF HEARING LOSS IN CONGENITAL CMV INFECTION$157,141
P01 · FY2002 · AI
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$286,522
R01 · FY2001 · DC
MECHANISMS AND ANTIVIRAL THERAPY OF HEARING LOSS IN CONGENITAL CMV INFECTION$157,141
P01 · FY2001 · AI
CONGENITAL CMV INFECTION IN OFFSPRING OF IMMUNE MOTHERS$283,477
R01 · FY2000 · DC
MECHANISMS AND ANTIVIRAL THERAPY OF HEARING LOSS IN CONGENITAL CMV INFECTION$184,822
P01 · FY2000 · AI